Reduced valve replacement surgery and complication rate in Staphylococcus aureus endocarditis patients receiving acetyl-salicylic acid

Journal of Infection

Volumn 58, Issue 5, 2009, Pages 332-338

  Eisen, Damon P ^a   Corey, G Ralph ^b   McBryde, Emma S ^a   Fowler Jr , Vance G ^b   Miro, Jose M ^c   Cabell, Chris H ^b   Street, Alan C ^a   Paiva, Marcelo Goulart ^d   Ionac, Adina ^e   Tan, Ru San ^f   Tribouilloy, Christophe ^g   Pachirat, Orathai ^h   Jones, Sandra Braun ⁱ   Chipigina, Natalia ^j   Naber, Christoph ^k   Pan, Angelo ^l   Ravasio, Veronica ^m   Gattringer, Rainer ⁿ   Chu, Vivian H ^b   Bayer, Arnold S ^o  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF BARCELONA   (Spain)

^d Hospital 9 de Julho   (Brazil)

^e VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^f National Hospital   (Singapore)

^g Amiens North Hospital   (France)

^h KHON KAEN UNIVERSITY   (Thailand)

ⁱ Rheumatology Service   (Chile)

^j PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^k UNIVERSITY OF DUISBURG ESSEN   (Germany)

^l UNIVERSITY OF BRESCIA   (Italy)

^m OSPEDALI RIUNITI   (Italy)

ⁿ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^o UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Acetyl salicylic acid; Endocarditis; Staphylococcus aureus; Surgery

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

ARTICLE; BACTERIAL ENDOCARDITIS; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; EMBOLISM; FEMALE; HEART ABSCESS; HEART VALVE REGURGITATION; HEART VALVE REPLACEMENT; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROGNOSIS; STAPHYLOCOCCUS AUREUS;

AGED; ASPIRIN; COHORT STUDIES; EMBOLISM; ENDOCARDITIS, BACTERIAL; FEMALE; HEART FAILURE; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STROKE; TREATMENT OUTCOME;

EID: 67349225427     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2009.03.006     Document Type: Article

References (24)

1. Fowler Jr. V.G., Miro J.M., Hoen B., Cabell C.H., Abrutyn E., Rubinstein E., et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293 (2005) 3012-3021
2. Uslan D.Z., Sohail M.R., St Sauver J.L., Friedman P.A., Hayes D.L., Stoner S.M., et al. Permanent pacemaker and implantable cardioverter defibrillator infection: a population-based study. Arch Intern Med 167 (2007) 669-675
3. Baddour L.M., Wilson W.R., Bayer A.S., Fowler Jr. V.G., Bolger A.F., Levison M.E., et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 111 (2005) e394-434
4. Kupferwasser L.I., Yeaman M.R., Nast C.C., Kupferwasser D., Xiong Y.Q., Palma M., et al. Salicylic acid attenuates virulence in endovascular infections by targeting global regulatory pathways in Staphylococcus aureus. J Clin Invest 112 (2003) 222-233
5. Nicolau D.P., Marangos M.N., Nightingale C.H., and Quintiliani R. Influence of aspirin on development and treatment of experimental Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 39 (1995) 1748-1751
6. Kupferwasser L.I., Yeaman M.R., Shapiro S.M., Nast C.C., Sullam P.M., Filler S.G., et al. Acetylsalicylic acid reduces vegetation bacterial density, hematogenous bacterial dissemination, and frequency of embolic events in experimental Staphylococcus aureus endocarditis through antiplatelet and antibacterial effects. Circulation 99 (1999) 2791-2797
7. Nicolau D.P., Tessier P.R., and Nightingale C.H. Beneficial effect of combination antiplatelet therapy on the development of experimental Staphylococcus aureus endocarditis. Int J Antimicrob Agents 11 (1999) 159-161
8. Anavekar N.S., Tleyjeh I.M., Mirzoyev Z., Steckelberg J.M., Haddad C., Khandaker M.H., et al. Impact of prior antiplatelet therapy on risk of embolism in infective endocarditis. Clin Infect Dis 44 (2007) 1180-1186
9. Cabell C.H., and Abrutyn E. Progress toward a global understanding of infective endocarditis. Early lessons from the International Collaboration on Endocarditis investigation. Infect Dis Clin North Am 16 (2002) 255-272 vii
10. Li J.S., Sexton D.J., Mick N., Nettles R., Fowler Jr. V.G., Ryan T., et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 30 (2000) 633-638
11. Hurst J.W., Morris D.C., and Alexander R.W. The use of the New York Heart Association's classification of cardiovascular disease as part of the patient's complete Problem List. Clin Cardiol 22 (1999) 385-390
12. McDonald J.R., Olaison L., Anderson D.J., Hoen B., Miro J.M., Eykyn S., et al. Enterococcal endocarditis: 107 cases from the international collaboration on endocarditis merged database. Am J Med 118 (2005) 759-766
13. Miro J.M., Anguera I., Cabell C.H., Chen A.Y., Stafford J.A., Corey G.R., et al. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin Infect Dis 41 (2005) 507-514
14. Taha T.H., Durrant S.S., Mazeika P.K., Nihoyannopoulos P., and Oakley C.M. Aspirin to prevent growth of vegetations and cerebral emboli in infective endocarditis. J Intern Med 231 (1992) 543-546
15. Sedlacek M., Gemery J.M., Cheung A.L., Bayer A.S., and Remillard B.D. Aspirin treatment is associated with a significantly decreased risk of Staphylococcus aureus bacteremia in hemodialysis patients with tunneled catheters. Am J Kidney Dis 49 (2007) 401-408
16. Chan K.L., Dumesnil J.G., Cujec B., Sanfilippo A.J., Jue J., Turek M.A., et al. A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis. J Am Coll Cardiol 42 (2003) 775-780
17. Chan K.L., Tam J., Dumesnil J.G., Cujec B., Sanfilippo A.J., Jue J., et al. Effect of long-term aspirin use on embolic events in infective endocarditis. Clin Infect Dis 46 (2008) 37-41
18. Eisen D.P., and Bayer A.S. Aspirin use in infective endocarditis. Clin Infect Dis 46 (2008) 1841-1842
19. Remadi J.P., Habib G., Nadji G., Brahim A., Thuny F., Casalta J.P., et al. Predictors of death and impact of surgery in Staphylococcus aureus infective endocarditis. Ann Thorac Surg 83 (2007) 1295-1302
20. Palma M., Bayer A., Kupferwasser L.I., Joska T., Yeaman M.R., and Cheung A. Salicylic acid activates sigma factor B by rsbU-dependent and -independent mechanisms. J Bacteriol 188 (2006) 5896-5903
21. Que Y.A., Haefliger J.A., Piroth L., Francois P., Widmer E., Entenza J.M., et al. Fibrinogen and fibronectin binding cooperate for valve infection and invasion in Staphylococcus aureus experimental endocarditis. J Exp Med 201 (2005) 1627-1635
22. Xiong Y.Q., Willard J., Yeaman M.R., Cheung A.L., and Bayer A.S. Regulation of Staphylococcus aureus alpha-toxin gene (hla) expression by agr, sarA, and sae in vitro and in experimental infective endocarditis. J Infect Dis 194 (2006) 1267-1275
23. Bayer A.S., Ramos M.D., Menzies B.E., Yeaman M.R., Shen A.J., and Cheung A.L. Hyperproduction of alpha-toxin by Staphylococcus aureus results in paradoxically reduced virulence in experimental endocarditis: a host defense role for platelet microbicidal proteins. Infect Immun 65 (1997) 4652-4660
24. Levison M.E., Carrizosa J., Tanphaichitra D., Schick P.K., and Rubin W. Effect of aspirin on thrombogenesis and on production of experimental aortic valvular Streptococcus viridans endocarditis in rabbits. Blood 49 (1977) 645-650